Cleyde S.C. Marconi

Mrs. Cleyde S.C. Marconi

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
Cleyde S.C. MarconiCleyde S.C. Marconi
Cleyde S.C. Marconi
Liliane Lins-KustererLiliane Lins-Kusterer
Liliane Lins-Kusterer
Carlos BritesCarlos Brites
Carlos Brites
MGMansueto Gomes-Neto
Mansueto Gomes-Neto
INTRODUCTION: Human immunodeficiency virus (HIV) and human T-cell leukemia virus-1 (HTLV-1) viruses are associated with a high global burden of disease, and coinfection is a frequently reported event. We aimed to compare the functioning and health-related quality of life (HRQoL) of patients infected with HTLV-1, HIV, and HIV-HTLV-1. METHODS: We conducted a cross-sectional study of patients older than 18 years who had an HTLV-1 infection (Group A), HIV infection (Group B), or HIV-HTLV-1 coinfection (Group C). The functioning profiles were evaluated using handgrip strength, Berg balance scale (BBS), timed “up and go” (TUG) test, and 5-m walk test (m/s). We used the World Health Organization Disability Assessment Schedule (WHODAS 2.0) questionnaire to measure disability. The HRQoL was evaluated using a 36-item short-form health survey. For data with parametric and non-parametric distribution, we used analysis of variance with Bonferroni correction and the Kruskal-Wallis test, followed by Dunn’s pairwise tests with Bonferroni correction. RESULTS: We enrolled 68 patients in Group A, 39 in Group B, and 29 in Group C. The scores for handgrip strength, BBS, TUG test, all the WHODAS domains, and HRQoL were poorer for Groups A and C than for Group B. CONCLUSIONS: Compared to patients with HIV infection, those with HIV-HTLV-1 coinfection and HTLV-1 infection had poor functioning and HRQoL scores. HTLV-1 infection was associated with reduced functioning and HRQoL in patients with a single HTLV-1 infection and HIV-HTLV-1 coinfection.

27 August 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
TFTatiana Ferreira Muniz Fernandez
Tatiana Ferreira Muniz Fernandez
Cleyde S.C. MarconiCleyde S.C. Marconi
Cleyde S.C. Marconi
IMIris Montaño-Castellon
Iris Montaño-Castellon
FDFelice Deminco
Felice Deminco
Carlos BritesCarlos Brites
Carlos Brites
Human T-cell lymphotropic virus (HTLV) infection affects over ten million people worldwide, but there is no effective treatment so far. This review describes the virological, immunological, and clinical outcomes of antiretroviral therapy (ART) in people with HTLV infection. This systematic review followed PRISMA reporting guidelines and was registered in PROSPERO: CRD42022350076. The Newcastle–Ottawa Scale, adapted for cross-sectional studies, and Rob-2 were used to assess the methodological quality of these studies. Systematic searches were conducted in the Medline (PubMed), Scopus (Elsevier), Cochrane Library, and Web of Science (Clarivate Analytics) databases. We retrieved data from eight methodologically diverse articles on treatment of patients infected by HTLV-1 or HTLV-2 alone, or coinfected by HIV-1, who received Raltegravir, Tenofovir, Lamivudine, or Zidovudine. The proviral load decreased in three out of seven studies over 4 to 48 weeks of antiretroviral use. Cellular immune response (CD4, CD8, CD25, CD69, and CD71 cells) was evaluated in six studies. While no significant clinical improvement was observed, all studies reported clinical stability during treatment. Despite the demonstrated antiviral activity of ART, in vitro, clinical improvement was not proven. Most studies showed disease stability during ART use, suggesting potential clinical benefits. There is a need of larger, well-controlled trials to define the role of ART in the treatment of HTLV infection.

11 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
TFTatiana Ferreira Muniz Fernandez
Tatiana Ferreira Muniz Fernandez
Cleyde S.C. MarconiCleyde S.C. Marconi
Cleyde S.C. Marconi
IMIris Montaño-Castellon
Iris Montaño-Castellon
FDFelice Deminco
Felice Deminco
Carlos BritesCarlos Brites
Carlos Brites
Human T-cell lymphotropic virus (HTLV) infection lacks effective treatment. This review describes the virological, immunological and clinical outcomes of antiretroviral therapy (ART) in people with HTLV infection. This systematic review followed PRISMA reporting guidelines and was registered in PROSPERO: CRD42022350076. The Newcastle-Ottawa Scales, adapted for cross-sectional studies, and Rob-2 were employed to assess the methodological quality of studies. A systematic search was conducted in Medline (PubMed), Scopus (Elsevier), Cochrane Library, and Web of Science (Clarivate Analytics) databases. We retrieved data from 08 methodologically diverse articles, on treatment of patients infected by HTLV-1 or HTLV-2 alone, or coinfected by HIV-1 with Raltegravir, Tenofovir, Lamivudine and Zidovudine. Proviral load decreased in 3 of 7 studies, during 4 to 48 weeks of antiretrovirals use. Cellular immune response (CD4, CD8, CD25, CD69 and CD71 cells) were evaluated in six studies. There was no significant clinical improvement in the studies but all of them detected clinical stability during treatment. Despite the demonstrated antiviral activity of ART, in vitro, clinical improvement was not proven. Most studies showed disease stability during ART use, suggesting potential clinical benefits. There is a need of larger, well-controlled trials, to define the role of ART for treatment of HTLV infection.

2 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
RCRóger J. Costa
Róger J. Costa
ASAndreas Stocker
Andreas Stocker
Cleyde S.C. MarconiCleyde S.C. Marconi
Cleyde S.C. Marconi
GCGubio S. Campos
Gubio S. Campos
SSSílvia I. Sardi
Sílvia I. Sardi
ENEduardo Martins Netto
Eduardo Martins Netto
Background: The co-circulation of multiple arboviruses with similar clinical presentations poses a significant challenge for public health surveillance. This study aimed to develop and clinically validate a novel multiplex RT-qPCR assay for the simultaneous detection of five arboviruses in three reactions. Methods: A diagnostic accuracy study was conducted in Salvador, Brazil. Evaluation was performed using 254 prospective serum samples and 34 archived positive samples. The primers and probes for the assay were designed in silico, all targeting highly conserved regions of Dengue (DENV), Zika (ZIKV), Chikungunya (CHIKV), Oropouche (OROV), and West Nile (WNV) viruses. The protocol was optimized in three reactions with a single thermal cycle, comprising a tetraplex reaction (DENV, CHIKV, ZIKV, and hRNAseP, an endogenous control) and two singleplex reactions (OROV and WNV). Results: In prospective analysis, the assay identified 45 DENV, 3 CHIKV, and 9 OROV-positive cases. Diagnostic accuracy for DENV and CHIKV was 96% (95% CI: 93.3–98.0%), successfully detecting four DENV cases missed by the reference standard. Furthermore, incorporating OROV enabled the identification of nine cases that conventional triplex protocols would have overlooked. Conclusion: This single-cycling multiplex RT-qPCR assay enhances epidemiological surveillance by expanding detection beyond traditional triplex targets to include OROV and WNV. This operational optimization reduces turnaround times and prevents the underdiagnosis of emerging arboviruses, serving as a robust diagnostic tool for endemic regions.

15 July 2026 in Tropical Medicine & International Health
Verified
Journal Article
Open access
RCRóger J. Costa
Róger J. Costa
Cleyde S.C. MarconiCleyde S.C. Marconi
Cleyde S.C. Marconi
GJGleice K. Jesus
Gleice K. Jesus
Gabriel Oliveira Santos FrancoGabriel Oliveira Santos Franco
Gabriel Oliveira Santos Franco
ASAbevailton M. Silva
Abevailton M. Silva
ENEduardo Martins Netto
Eduardo Martins Netto
Background: Chikungunya virus (CHIKV) is an arbovirus that causes an acute febrile illness with intense muscle and joint pain, with the possibility of progressing to a chronic or neurological stage. We conducted a systematic review and meta‐analysis with the aim of evaluating the accuracy of real‐time reverse transcriptase polymerase chain reaction (RT‐qPCR) protocols for detecting CHIKV during the acute phase of symptoms. Methods: We searched the literature until December 5, 2024, including English, Portuguese, and Spanish, with no time restriction in PubMed, LILACS, and Web of Science. Studies that evaluated RT‐qPCR protocols compared to reference techniques such as viral isolation or validated RT‐qPCRs were included in the study. We collected data on sensitivity, specificity, accuracy, study design and methodological characteristics of RT‐qPCR. Quadas‐2 tool was used to assess the risk of bias and applicability. Subsequently, a meta‐analysis and meta‐regression were performed. Results: Twenty‐eight protocols were included in this systematic review, 28 index tests were extracted and 24 were included in quantitative analysis. According to meta‐analysis, RT‐qPCR for CHIKV detection had a combined accuracy of 96% (95% CI: 94 to 99%) and a summary sensitivity and specificity of 99.7% and 99.7%, respectively; however, the results need to be interpreted considering the high heterogeneity (78.1%) and publication bias ( p = 0.002). Conclusion: RT‐qPCR is a highly accurate technique for detecting the Chikungunya virus during the acute phase of symptoms. Despite the high heterogeneity observed, all subgroup analyses demonstrated high overall performance.